Otsuka, Bristol-Myers Squibb Withdraw Abilify Extension Application In Europe
This article was originally published in PharmAsia News
Executive Summary
Japan's fifth-largest drug maker Otsuka Pharmaceutical withdrew its application in Europe for the additional indication of major depressive episodes for its best-selling atypical antipsychotic Abilify (aripiprazole), the European Medicines Agency announced Nov. 19